The proceeds from the round will be used to develop and commercialize Obexelimab, the company’s leading drug candidate used in the treatment of IgG4-related disease, according to a Nov. 7 Zenas news release provided to Becker’s.
The company plans to launch a phase 3 registration trial for Obexelimab in late 2022 and launch the company’s other autoimmune disease programs in 2023, the release said.
Enavate Sciences led the funding round.
